Center for Continuous Flow Synthesis and Processing (CCFLOW), Research Center Pharmaceutical Engineering GmbH (RCPE), Inffeldgasse 13, 8010 Graz, Austria.
Institute of Chemistry, University of Graz, Heinrichstrasse 28, 8010 Graz, Austria.
Acc Chem Res. 2020 Jul 21;53(7):1330-1341. doi: 10.1021/acs.accounts.0c00199. Epub 2020 Jun 16.
In recent years, a steadily growing number of chemists, from both academia and industry, have dedicated their research to the development of continuous flow processes performed in milli- or microreactors. The common availability of continuous flow equipment at virtually all scales and affordable cost has additionally impacted this trend. Furthermore, regulatory agencies such as the United States Food and Drug Administration actively encourage continuous manufacturing of active pharmaceutical ingredients (APIs) with the vision of quality and productivity improvements. That is why the pharmaceutical industry is progressively implementing continuous flow technologies. As a result of the exceptional characteristics of continuous flow reactors such as small reactor volumes and remarkably fast heat and mass transfer, process conditions which need to be avoided in conventional batch syntheses can be safely employed. Thus, continuous operation is particularly advantageous for reactions at high temperatures/pressures (novel process windows) and for ultrafast, exothermic reactions (flash chemistry).In addition to conditions that are outside of the operation range of conventional stirred tank reactors, reagents possessing a high hazard potential and therefore not amenable to batch processing can be safely utilized (forbidden chemistry). Because of the small reactor volumes, risks in case of a failure are minimized. Such hazardous reagents often are low molecular weight compounds, leading generally to the most atom-, time-, and cost-efficient route toward the desired product. Ideally, they are generated from benign, readily available and cheap precursors within the closed environment of the flow reactor on-site on-demand. By doing so, the transport, storage, and handling of those compounds, which impose a certain safety risk especially on a large scale, are circumvented. This strategy also positively impacts the global supply chain dependency, which can be a severe issue, particularly in times of stricter safety regulations or an epidemic. The concept of the in situ production of a hazardous material is generally referred to as the "generator" of the material. Importantly, in an integrated flow process, multiple modules can be assembled consecutively, allowing not only an in-line purification/separation and quenching of the reagent, but also its downstream conversion to a nonhazardous product.For the past decade, research in our group has focused on the continuous generation of hazardous reagents using a range of reactor designs and experimental techniques, particularly toward the synthesis of APIs. In this Account, we therefore introduce chemical generator concepts that have been developed in our laboratories for the production of toxic, explosive, and short-lived reagents. We have defined three different classes of generators depending on the reactivity/stability of the reagents, featuring reagents such as Br, HCN, peracids, diazomethane (CHN), or hydrazoic acid (HN). The various reactor designs, including in-line membrane separation techniques and real-time process analytical technologies for the generation, purification, and monitoring of those hazardous reagents, and also their downstream transformations are presented. This Account should serve as food for thought to extend the scope of chemical generators for accomplishing more efficient and more economic processes.
近年来,越来越多的化学家(包括学术界和工业界的)致力于开发在毫微微反应器中进行的连续流动过程。几乎在所有规模上都可以获得连续流动设备,并且价格合理,这也推动了这一趋势。此外,美国食品和药物管理局等监管机构积极鼓励连续制造活性药物成分(APIs),以期提高质量和生产力。这就是制药行业正在逐步采用连续流动技术的原因。由于连续流动反应器具有小的反应器体积和非常快的热传递和质量传递等特殊特性,因此可以安全地采用在常规间歇合成中需要避免的工艺条件。因此,连续操作特别有利于在高温/高压下进行的反应(新的工艺窗口)和超快的放热反应(闪光化学)。除了常规搅拌釜反应器的操作范围之外的条件外,还可以安全地利用具有高危害潜力且因此不适于批量处理的试剂(禁止化学)。由于反应器体积小,因此在发生故障时的风险最小化。此类危险试剂通常是低分子量化合物,通常可以使所需产物的原子,时间和成本效率最高。理想情况下,它们是由在流动反应器的封闭环境中从良性,易于获得且廉价的前体就地按需生成的。这样,就避免了对化合物的运输,储存和处理,这些化合物尤其是在大规模情况下会带来一定的安全风险。该策略还对全球供应链的依赖性产生了积极影响,这在安全法规更为严格或发生流行病时可能是一个严重的问题。在原位生产危险材料的概念通常被称为该材料的“发生器”。重要的是,在集成的流动过程中,可以连续组装多个模块,不仅可以在线进行试剂的纯化/分离和淬灭,还可以将其下游转化为非危险产品。在过去的十年中,我们小组的研究重点是使用一系列反应器设计和实验技术连续生成危险试剂,特别是针对 API 的合成。因此,在本报告中,我们介绍了为生产有毒,易爆和短寿命试剂而在我们的实验室中开发的化学发生器概念。我们根据试剂的反应性/稳定性定义了三种不同类别的发生器,其特点是试剂例如 Br,HCN,过酸,重氮甲烷(CHN)或氢叠氮酸(HN)。还介绍了各种反应器设计,包括在线膜分离技术和实时过程分析技术,用于生成,纯化和监测这些危险试剂,以及它们的下游转化。本报告应作为进一步扩展化学发生器范围以实现更高效和更经济的过程的思路。